OKYO Pharma
Develops urcosimod eye drops for neuropathic corneal pain and anterior-segment eye diseases.
Something off on this page? Send us feedback.
Profile
Develops drug candidates for neuropathic corneal pain and anterior-segment eye diseases. The clinical-stage pipeline centers on urcosimod, a preservative-free eye drop, with a preclinical rare-corneal-disease program and discovery-stage OK-201.
Develops drug candidates for neuropathic corneal pain (NCP) and anterior-segment eye diseases. The clinical-stage pipeline centers on urcosimod, formerly OK-101, a preservative-free, non-opioid eye drop with pain-relieving and anti-inflammatory activity. A randomized, placebo-controlled NCP study has been completed, and the company is planning a global pivotal trial.
Alongside urcosimod, the pipeline includes a preclinical program for rare corneal disease and discovery-stage OK-201. Development is planned globally, with a principal executive office in Guernsey and Nasdaq as the principal trading market. The business depends on clinical development, regulatory progression, and financing through urcosimod, including an at-the-market equity facility.
Company facts
Key statistics
Year to date −26.0% · Average volume (30d) 95.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior target | Target |
|---|---|---|---|---|
| Jul 13, 2026 | H.C. Wainwright | Target | $7 | $5 |
| Jan 29, 2026 | H.C. Wainwright | Target | $7 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | −$0.08 | −$0.15 | −87.5% | — | — | — | +5.11% |
| Jun 3, 2026Q4 FY26 | −$0.08 | −$0.04 | +49.8% | — | — | — | +1.20% |
| Jan 30, 2026 | −$0.07 | −$0.01 | +85.7% | — | — | — | +1.95% |
| Jan 29, 2025 | — | −$0.08 | — | — | — | — | +2.80% |
Financial highlights
| 12 quarters | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$2.1K | −$3.4K | $0 | −$1.3K | −$885 | −$935 | |
| Operating income | −$8.7M | −$7.0K | −$3.0M | −$4.2M | −$2.8M | −$6.4M | |
| Net income | −$8.8M | — | −$2.7M | −$2.0M | −$2.6M | −$6.4M | |
| Diluted EPS | −$0.00 | −$0.00 | −$0.08 | −$0.04 | −$0.07 | −$0.17 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Balance sheet, Mar 31, 2026Cash & short-term investments $20.6M · Total debt $0 · Total assets $21.0M · Shareholders' equity $12.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 38.37M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Gabriele M. Cerrone · director, 10 percent owner: | 21.40M | 55.78% | Form 4 | Aug 7, 2026 |
| Sirenia Capital Management LP | 4.05M | 7.70% | 13G | May 15, 2026 |
| Chernett Jorey | 3.80M | 9.50% | 13G | Feb 13, 2026 |
| Woodline Partners LP | 3.65M | 7.00% | 13G | May 15, 2026 |
| Laura Natalia Monica Fonda | 1.93M | 5.01% | 13G | Oct 29, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 27, 2026 | Rajkumar V. Patil | officer: Chief Scientific Officer | +3,363 | $1.49 |
| Jul 21, 2026 | Flavio Mantelli | officer: CHIEF MEDICAL OFFICER | +20,000 | $1.40 |
| Jul 20, 2026 | Gabriele M. Cerrone | director, 10 percent owner: | +25,000 | $1.40 |
| Jul 21, 2026 | Gabriele M. Cerrone | director, 10 percent owner: | +22,500 | $1.45 |
| Jul 21, 2026 | Gary S. Jacob | director, officer: CHIEF DEVELOPMENT OFFICER | +3,500 | $1.40 |
Peers
- Bausch + Lomb
Dry-eye medicines XIIDRA and MIEBO; ocular-surface portfolio
- Harrow
VEVYE and a broad North American ocular-surface portfolio
- Aldeyra Therapeutics
Investigational reproxalap for dry-eye disease
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OKYO Pharma | $1.64 | −0.61% | $64.1M | — | — | — | — |
| Bausch + Lomb | $17.15 | 0.00% | $6.13B | — | 17.2 | 1.2 | +9.1% |
| Harrow | $37.77 | +1.29% | $1.39B | — | 30.3 | 5.0 | +10.9% |
| Aldeyra Therapeutics | $1.51 | +1.68% | $89.6M | — | — | — | — |
| Median | — | 23.8 | 3.1 | +10.0% |